Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 10 clients • 13 examiners • 11 art units • 0 of 14 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
BELL & ASSOCIATES operates within the Biotechnology & Pharmaceuticals technology area, managing 547 career applications. The firm has secured a resolved allowance rate pct of 76.88. This metric tracks the firm's results in obtaining allowances for its clients within the life sciences field.
On average, the firm receives 2.88 avg office actions per allowance before reaching a final disposition. There are 13 pending office actions currently active. The 2.88 avg office actions per allowance provides a measure of the typical interaction required between the firm and the patent office to reach a grant. With 13 pending office actions, the firm continues its work in this technical domain.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (14%) |
| §112 only | 4 (29%) |
| Double-patenting + other | 3 (21%) |
| Multi-statute (no §101) | 4 (29%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 2 | 76.5% | +8.0% |
| WEDDLE, ALEXANDER MARION | 1 | 63.6% | +25.6% |
| SAEED, KAMAL A | 1 | 83.9% | +9.8% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| BAUER, BRIANNA LEE | 1 | 100.0% | +0.0% |
| SHAMEEM, GOLAM M | 1 | 86.7% | +16.0% |
| THOMAS, SOUMYA | 1 | 60.0% | -16.7% |
| CESARE, JOSEPH DAVID | 1 | — | — |
| VISHNYAKOVA, ELENA VLADIMIROVNA | 1 | 65.8% | +51.3% |
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704068 | COMPOSITION FOR PREVENTING OR TREATING GRAVES' DISEASE COMPRISING COMPOUND CONTAINING AN IMIDAZOPYRIDINE STRUCTURE AS ACTIVE INGREDIENT | SAEED, KAMAL A | — |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | SHAMEEM, GOLAM M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035429 | APPLICATION OF ISOQUINOLINE COMPOUND IN TUMOR TREATMENT | BURKETT, DANIEL JOHN | 53d |
| 18861225 | METHOD FOR PRODUCING ENAMELS FOR VEHICLE BODYWORK AND COMPOSITION OF THE PAINT | WEDDLE, ALEXANDER MARION | — |
| 18684789 | APPLICATION OF BENZANILIDE COMPOUND IN TUMOR TREATMENT | SEAMAN, D MARGARET M | — |
| 18685925 | APPLICATION OF HYDRAZIDE COMPOUND IN TUMOR TREATMENT | BAUER, BRIANNA LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035429 | APPLICATION OF ISOQUINOLINE COMPOUND IN TUMOR TREATMENT | BURKETT, DANIEL JOHN | 53d |
| 18861225 | METHOD FOR PRODUCING ENAMELS FOR VEHICLE BODYWORK AND COMPOSITION OF THE PAINT | WEDDLE, ALEXANDER MARION | — |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | SHAMEEM, GOLAM M | — |
| 18268236 | BENZENE RING COMPOUND AND USE THEREOF | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| Art Unit | Apps |
|---|---|
| 1712 | 1 |
| 1625 | 1 |
| 1626 | 1 |
| 1621 | 1 |
| 2664 | 1 |
| 1618 | 1 |
| 1691 | 1 |
| 1624 | 1 |
| 1658 | 1 |
| 1638 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18942833 | HALOGENATED BENZYLIDINE DERIVATIVES | Renovel Innovations, Inc. | SEAMAN, D MARGARET M | §102DP | Non-Final OA | — | Pending | Nov 11, 2024 | |
| 18861225 | METHOD FOR PRODUCING ENAMELS FOR VEHICLE BODYWORK AND COMPOSITION OF THE PAINT | Industrias Proa, S.A. | WEDDLE, ALEXANDER MARION | 1712 | §103§112 | Final Rejection | — | Pending | Oct 29, 2024 |
| 18704068 | COMPOSITION FOR PREVENTING OR TREATING GRAVES' DISEASE COMPRISING COMPOUND CONTAINING AN IMIDAZOPYRIDINE STRUCTURE AS ACTIVE INGREDIENT | Esgelbio Inc. | SAEED, KAMAL A | §112 | Non-Final OA | — | Pending | Apr 24, 2024 | |
| 18686461 | APPLICATION OF TETRACYCLINE COMPOUND IN TREATMENT OF TUMOR | Nanjing Shijiang Medicine Technology Co., Ltd. | SHIAO, REI TSANG | §103 | Final Rejection | — | Pending | Apr 22, 2024 | |
| 18684789 | APPLICATION OF BENZANILIDE COMPOUND IN TUMOR TREATMENT | Nanjing Shijiang Medicine Technology Co., Ltd. | SEAMAN, D MARGARET M | 1625 | §102§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18685925 | APPLICATION OF HYDRAZIDE COMPOUND IN TUMOR TREATMENT | Nanjing Shijiang Medicine Technology Co., Ltd. | BAUER, BRIANNA LEE | 1626 | §102§103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | Nanjing Shijiang Medicine Technology Co., Ltd. | SHAMEEM, GOLAM M | 1621 | §112 | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18437291 | A System for Tracking, Locating and Calculating the Position of a First Moving Object in Relation to a Second Object | Hall, Matthew | THOMAS, SOUMYA | 2664 | §103Other | Final Rejection | — | Pending | Feb 09, 2024 |
| 18562298 | ANTI-PD-1 POLYPEPTIDES AND THEIR USE | Beijing Kanova Biopharmaceutical Co., Ltd. | CESARE, JOSEPH DAVID | 1618 | §112 | Non-Final OA | — | Pending | Nov 18, 2023 |
| 18268236 | BENZENE RING COMPOUND AND USE THEREOF | Nanjing Shijiang Medicine Technology Co., Ltd. | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103DP | Final Rejection | — | Pending | Jun 18, 2023 |
| 18035429 | APPLICATION OF ISOQUINOLINE COMPOUND IN TUMOR TREATMENT | Tongji University | BURKETT, DANIEL JOHN | 1624 | §102§112 | Non-Final OA | 53d | Pending | May 04, 2023 |
| 17641539 | APPLICATION OF NON-IGF1R-BINDING SUBSTANCE IN PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASES | Shanghai Institute Of Nutrition And Health, Chinese Academy Of Sciences | STEELE, AMBER D | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Aug 23, 2022 |
| 17292296 | USE OF ECM1 GENE-KNOCKOUT MOUSE IN SCREENING OF ANTI-HEPATIC FIBROSIS DRUG | Center For Excellence In Molecular Cell Science, Chinese Academy Of Sciences | ROGERS, ERIC JASON | 1638 | §112 | Non-Final OA | 8d | Pending | Sep 15, 2021 |
| 17050168 | REPEAT-MEDIATED PLANT SITE-SPECIFIC RECOMBINATION METHOD | Cas Center For Excellence In Molecular Plant Sciences | BYRNES, DAVID R | 1662 | — | Final Rejection | 1d overdue | Pending | Oct 23, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial